<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01836653</url>
  </required_header>
  <id_info>
    <org_study_id>ATOM</org_study_id>
    <secondary_id>UMIN000010209</secondary_id>
    <nct_id>NCT01836653</nct_id>
  </id_info>
  <brief_title>Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases</brief_title>
  <acronym>ATOM</acronym>
  <official_title>Randomized Phase II Study of mFOLFOX6 + Bevacizumab or mFOLFOX6 + Cetuximab in Liver Only Metastasis From KRAS Wild Type Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EPS Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EPS Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of mFOLFOX6+bevacizumab and
      mFOLFOX6+cetuximab for liver only metastasis from KRAS Exon 2 wild type (under protocol
      1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition) colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Description: The purpose of this study is to evaluate efficacy and safety of
      mFOLFOX6+bevacizumab and mFOLFOX6+cetuximab for liver only metastasis from KRAS Exon 2 wild
      type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition)
      colorectal cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>assessed every 8 weeks, up to 4 years</time_frame>
    <description>assessed by Independent Review Committee</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>assessed every 8 weeks, up to 4 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Tumor shrinkage rate at 8 week</measure>
    <time_frame>assessed at 8 week, up to 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Liver resection rate</measure>
    <time_frame>assessed every 8 weeks, up to 4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>R0 liver resection rate</measure>
    <time_frame>assessed every 8 weeks, up to 4 years</time_frame>
    <description>pathologically confirmed R0 liver resection rate</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>assessed every 8 weeks, up to 4 years</time_frame>
    <description>assessed by investigators</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to treatment-failure</measure>
    <time_frame>assessed every 2 weeks, up to 4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>assessed every 2 weeks, up to 4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>assessed every 16 weeks, up to 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>assessed every 2 weeks, up to 4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Progression-free survival among the RAS wild type subpopulation</measure>
    <time_frame>assessed every 8 weeks, up to 4 years</time_frame>
    <description>All the assessment is repeated for a maximum of 4 years.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>mFOLFOX + Bmab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mFOLFOX plus bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mFOLFOX + Cmab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mFOLFOX plus cetuximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.</description>
    <arm_group_label>mFOLFOX + Bmab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.</description>
    <arm_group_label>mFOLFOX + Cmab</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-OHP</intervention_name>
    <description>85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.</description>
    <arm_group_label>mFOLFOX + Bmab</arm_group_label>
    <arm_group_label>mFOLFOX + Cmab</arm_group_label>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>l-LV</intervention_name>
    <description>200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.</description>
    <arm_group_label>mFOLFOX + Bmab</arm_group_label>
    <arm_group_label>mFOLFOX + Cmab</arm_group_label>
    <other_name>Levofolinate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.</description>
    <arm_group_label>mFOLFOX + Bmab</arm_group_label>
    <arm_group_label>mFOLFOX + Cmab</arm_group_label>
    <other_name>Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.</description>
    <arm_group_label>mFOLFOX + Bmab</arm_group_label>
    <arm_group_label>mFOLFOX + Cmab</arm_group_label>
    <other_name>Fluorouracil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histopathologically confirmed colorectal cancer (adenocarcinoma) excluding vermiform
             appendix cancer and proctos cancer.

          2. RAS wild type

          3. Synchronous* or metachronous liver limited meitastasis with no extrahepatic desiease

               -  shychronous liver limited metastasis with primary lesion less than two thirds of
                  the circumference

               -  patients with primary lesion more than two thirds of the circumference can be
                  enrolled after primary resection

          4. Patients who has one or more lesion(s) of diameter 1 cm or larger (RECEST v1.1) be
             able to assess continuously on the basis of the protocol by contrast enhanced CT or
             contrast enhanced MRI of the liver:

        (1)Liver metastases 5 or more (2)Liver metastases with 5 cm or larger in greatest dimension
        (3)Unresectable considering remaining hepatic function (4)Invasion into all hepatic veins
        or inferior vena cava (5)Invasion into both right and left hepatic arteries or portal veins
        5.No prior chemotherapy for colorectal cancer including hepatic arterial infusion.
        Excluding postoperative and preoperative chemoradiotherapy except for rectal cancer with
        synchronous liver metastases. Patients received postoperative chemotherapy containing
        oxaliplatin have to be enrolled after 24 weeks from the last oxaliplatin administration.

        6.No previous treatment including ablation therapy, cryotherapy and chemotherapy for
        metastases 7.Age at enrollment is &gt;=20 and =&lt;80 years 8.The Eastern Cooperative Oncology
        Group (ECOG) Performance Status 0-1 9.Life expectancy from the day of enrollment is 3
        months or longer 10.Major organ functions less than 14 days prior to entry meet the
        following criteria.

          1. Neu &gt;= 1500/mm3

          2. Pt &gt;= 10.0x10^4/mm3

          3. Hb &gt;= 9.0 g/dL

          4. T-bil =&lt; 2.0 mg/dL

          5. AST and ALT =&lt; 200 IU/L

          6. sCr =&lt; 1.20 mg/dL

          7. INR &lt; 1.5

          8. Proteinuria =&lt; 2+ 11.Written informed consent

        Exclusion Criteria:

          1. Previously experienced severe allergic reaction to drugs

          2. Receiving anti-platelet drugs (aspirin &gt;= 325 mg/day) or NSAIDs

          3. Receiving chronic systemic corticosteroid treatment

          4. Surgery/ biopsy with skin incision or traumatic injury with suture less than 14 days
             prior to entry. Excluding, suture for implanted venous reservoirs with catherter is
             allowed.

          5. Severe postoperative complications (e.g. postoperative infection, anastomic dehiscence
             or paralytic ileus)

          6. Diagnosed as hereditary colorectal cancer

          7. Active other malignancies

          8. Cerebrovascular disease or symptoms less than 1 year prior to entry

          9. Pleural effusion, ascites or cardiac effusion requiring drainage

         10. Hemorrhage/bleeding, paralytic ileus, obstruction or ulceration of gastrointestinal
             tract

         11. Perforation of gastrointestinal tract less than 1 year prior to entry

         12. Presence of active infection

         13. HBs antigen or HCV antibody positive

         14. Uncontrolled comorbidity including hypertension, diabetes, arrhythmia, or other
             diseases (such as cardiac disorder, interstitial pneumonia or renal disorder)

         15. Presence of &gt;= grade 2 diarrhea

         16. Presence of &gt;= grade 1 peripheral neuropathy

         17. Pregnant or lactating women. Women and men with childbearing potential unwilling to
             use effective means of contraception

         18. Psychosis or psychiatric symptoms who are not able to comply with the protocol

         19. Any other medical conditions disable to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoshihiko Maehara, MD,PhD,FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Graduate School of Medical Science, Kyushu University, Department of Surgery and Science</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Naohiro Tomita, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hyogo College of Medicine, Department of Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ichinosuke Hyodo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tsukuba University, Graduate School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michiaki Unno, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tohoku University, Division of Gastroenterological Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>EPS Corporation</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-0814</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2013</study_first_submitted>
  <study_first_submitted_qc>April 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2013</study_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bevacizumab</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>KRAS wild type colorectal cancer</keyword>
  <keyword>RAS wild type colorectal cancer</keyword>
  <keyword>liver metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

